News - Jevtana

Filter

Current filters:

Jevtana

Popular Filters

UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine

11-05-2012

Confirming previous negative guidance (The Pharma Letter January 12), UK drugs watchdog the National…

AllerganBotoxEuropeJevtanaNeurologicalOncologyPharmaceuticalPricingRegulationSanofi

Some advantages seen for Sanofi’s Jevtana by Germany’s IQWiG

25-01-2012

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

EuropeJevtanaOncologyPharmaceuticalPricingRegulationSanofi

Zytiga overtaking Provenge in MCRPC

17-01-2012

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone)…

BiotechnologyDendreonJanssenJevtanaJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeSanofiZytiga

Negative NICE guidance for Sanofi prostate cancer drug

12-01-2012

The UK’s drug watchdog the National Institute for Health and Clinical Excellence (NICE), has today…

EuropeJevtanaOncologyPharmaceuticalPricingRegulationSanofi

Back to top